Dual milestones mark a new chapter of national growth and impact for the Robert A. Winn Excellence in Clinical Trials Award Program.
PHILADELPHIA, PA – November 16, 2026 – Temple Health today announced that Fox Chase Cancer Center (Fox Chase) will become the new institutional home of the Robert A. Winn Excellence in Clinical Trials Award Program (Winn Awards) — one of the nation's leading initiatives to improve participation in clinical trials through education, leadership development, and community engagement. In another important milestone, the organization also announced that its founding funder, the Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization, has renewed its commitment that will extend support into the program’s next chapter. That support will fund cohorts through 2030 to advance the Winn Awards’ efforts to drive better health outcomes in all communities to save more lives.
This announcement marks a significant moment in the history of the program, reaffirming its mission to train current and emerging leaders in clinical research, and expanding its reach through Fox Chase’s role as a national leader in advanced cancer research and care delivery. The Winn Awards' additional funding partners — Gilead Sciences, Genentech, Amgen, and AstraZeneca — have also committed to extend their support into the program's next chapter.
“The Winn Awards have always been about so much more than training the next generation of clinical investigators; they are about making sure the benefits of scientific discovery are accessible to every community it is meant to serve,” said Robert A. Winn, MD, namesake of the program, National Advisory Committee Chair, and Cancer Center Director for Fox Chase Cancer Center. "Breakthroughs in medicine only change lives when they reach the people who need them. I am grateful to the leadership at Temple Health, Fox Chase, the BMS Foundation, and all of our funding partners, for their commitment to this next chapter of the program, and I look forward to seeing it continue advancing clinical research that delivers real-world impact."
The transition of the Winn Awards to its new institutional home follows the recent appointment of Dr. Winn as Cancer Center Director at Fox Chase. As the program's new institutional home, Fox Chase will build on the program's first five years of success while supporting continued collaboration among Winn Awards scholars and students, academic institutions, healthcare organizations, community partners, and funding partners.
“Expanding access to paradigm-shifting research and the clinical trials that drive innovation is at the heart of our mission,” said Robert Uzzo, MD, MBA, President and CEO of Fox Chase Cancer Center. “This vision, to broaden the reach of life-changing discoveries through education, mentorship, and collaboration, is one that we share with the Winn Awards, and one we believe will have a profound impact for years to come.”
“We are honored to welcome the Winn Awards to Temple,” said Abhi Rastogi, MBA, MIS, President and CEO of Temple Health, “and look forward to expanding the impact of a program that not only aligns so closely with our mission, but has become the national standard for developing clinical research leaders and improving participation in clinical trials.”
Established in 2020 through a landmark $100 million commitment from the BMS Foundation, the Winn Awards program was created to address one of the most persistent challenges in clinical research: ensuring that the patients who participate in clinical trials reflect the populations most affected by the diseases being studied. More representative clinical trials lead to better science, access to cutting-edge treatments, and greater confidence that new therapies are safe and effective for everyone they are intended to serve. Through a rigorous curriculum focused on research design, community engagement, and mentorship, the Winn Awards is equipping physicians-researchers, and future clinical trial leaders across the country to advance its mission of Better Science for All.
"The Winn Awards were built on a belief that better science requires broader research participation, and five years of success have shown that to be true,” said BMS Foundation President Catharine Grimes. “Fox Chase is the right home for this program's next chapter: a nationally recognized cancer center that is mission-aligned to expanding access to clinical trials and improving representation in communities nationwide. That is why the BMS Foundation is deepening its commitment through 2030 and why we are proud to do so alongside a growing coalition of partners who share our vision.
Since its launch, the Winn Awards has funded 361 early-stage physician investigators through its Winn Career Development Award (CDA) program in collaboration with AACR; 373 medical students through the Winn Clinical Investigator Pathway Program (CIPP); 11 Gilead Sciences Community Innovation Grants; and 18 Clinical Investigator Leadership Award (CILA) scholars implemented by Conquer Cancer, the ASCO Foundation, and the American Heart Association. Its programs have more than 90 participating institutions, over 150 faculty members, more than 300 mentors, and 40 National Advisory Committee members from across the United States working toward a common goal of improving clinical trial participation.
Winn CDA scholars throughout the nation, including alumni at Fox Chase, are actively addressing gaps in recruitment and retention of communities and patients who have been historically medically underserved. Today, Winn Award scholars and alumni are leading clinical trials, conducting community-engaged research, securing competitive grant funding, mentoring future investigators, and helping strengthen public trust in clinical research across the country.
“Receiving the Winn Award has been absolutely instrumental in helping Fox Chase further develop its Young Adult Cancer Program,” said Christopher G. Cann, MD, the program’s director and assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, and Winn CDA Scholar Cohort 5. “The mentorship and support I received helped me think through how to structure our trials, identify meaningful outcomes and build something that could realistically improve care for young adults with cancer.”
The Winn Awards is supported by BMS Foundation along with Gilead Sciences, Genentech, Amgen, and AstraZeneca, with curriculum and implementation partners including the American Association for Cancer Research (AACR), Conquer Cancer, the ASCO Foundation, and the American Heart Association. As the Winn Awards enters its next chapter, these funding and implementation partnerships will remain central to expanding its impact and helping ensure that advances in medicine benefit all communities across the country.
What Winn Awards funding partners are saying about the program's next chapter:
“Gilead is proud to support the Winn Awards and its mission to advance clinical research leadership and broaden participation in clinical trials,” said Jill Massey, PharmD, MBA, BCMAS, Vice President, Global Medical Strategy and Operations at Gilead Sciences. “We look forward to the program’s continued impact at Fox Chase Cancer Center.”
“Genentech is pleased to partner with the Winn Awards in their next phase of national growth,” said Jill Shotzberger, Executive Director of Strategy, Impact & Operations, U.S. Public Affairs & Access at Genentech. “Fox Chase Cancer Center provides an exceptional foundation to expand the program's national reach and accelerate the development of the next generation of clinical research leaders committed to advancing science for all patients.”
“Clinical trials can only move medicine forward when their findings reflect all people who have the condition that’s to be treated,” said Ponda Motsepe-Ditshego, MD, Vice President, Inclusive Global Health and Impact at Amgen. “The Winn Awards is building that foundation by preparing research leaders and showing measurable progress in broadening trial participation. Amgen is proud to support this work, and we’re excited to see its next chapter at Fox Chase bring its impact to Philadelphia and communities across the country.”
“We are enthusiastic about continuing our support for the Winn Clinical Investigator Pathway Program and its unique role in advancing the mission of Better Science For All,” said Roula Qaqish, Vice President, Head of Medical Affairs, US Oncology at AstraZeneca. “By giving medical students hands-on experience in community-engaged clinical research, Winn CIPP is helping prepare the next generation of investigators to broaden representation in clinical trials and ensure research better reflects the patients and communities we serve.”